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Second-generation percutaneous bioprosthetic
valve: A short-term study in sheep
Dusan Pavcnik, MD, PhD, John Kaufman, MD, Barry Uchida, BS, Luiz Correa, MD, Takao Hiraki,
MD, Seong Chang Kyu, MD, Frederick S. Keller, MD, and Josef Rosch, MD, Portland, Ore
Objectives: To eliminate occasional tilting of the original bioprosthetic venous valve (BVV) a second-generation BVV has
been developed. This study was performed to evaluate deployment, stability, and short-term function of the second-
generation BVV in an animal model.
Methods: A second-generation percutaneously placed BVV consisting of a square stent and lyophilized small intestinal
submucosa attached to a second square stent (DS BVV) or Z-stent (ZS BVV) were tested. DS BVVs (n  32) were
constructed with a nitinol (n  28) or stainless steel double stent (n  4), and ZS BVVs (n  16) were made of nitinol
(n 8) or stainless steel (n 4). BVVs were implanted percutaneously through a femoral vein approach into the jugular
vein in 24 female sheep with an over-the-wire 13F or 10F delivery system. All BVVs were placed across the natural valve
of the proximal jugular vein. Deployment, stability, and function of BVVs were studied at immediate venography with
contrast medium injections peripheral and central to the BVVs. Animals underwent follow-up venography and were
sacrificed at 6 weeks (n  24). Gross pathologic examination was performed.
Results: Jugular vein diameter ranged from 9.8 to 14.4 mm (mean, 12.1  1.2 mm) in 24 sheep. The 10-mm to 12-mm
valve was deployed in 27 jugular veins, and the 12-mm to 14-mm valve was deployed in 21 jugular veins. No tilting was
seen at placement of 48 BVVs into the jugular veins, and all valves exhibited good function on immediate venograms.
Angiographic competency for the nitinol and stainless steel ZS BVV (100%) was similar to that for the nitinol DS BVV
(92.3%; P .488) but was significantly better than for the stainless steel DS BVV at 6 weeks (50%; P .03). Dysfunction
of 4 valves was caused by either nitinol DS BVV oversizing (n 2) or intimal hyperplasia with the stainless steel DS BVV
(n  2).
Conclusion: Placement without tilting appears essential for proper valve function. The second-generation BVV enables
placement without tilting. Exact matching of valve size with vein diameter is necessary for good valve function. (J Vasc
Surg 2004;40:1223-7.)
Clinical Relevance: At present there are no widely accepted surgical or percutaneous treatment options for deep chronic
venous insufficiency. A manufactured, percutaneously implantable, nonimunogenic and nonthrombogenic bioprosthetic
venous valve that remains patent and competent over time is an attractive alternative to direct venous valve reconstruction
or transplantation. Our results and the potential for effective treatment with bioprosthetic venous valves warrants clinical
research in carefully selected patients and may lead to an effective, minimally invasive treatment for deep chronic venous
insufficiency.Several artificial valves for replacement of diseased or
absent venous valves by percutaneous implantation have
been experimentally developed over the last 10 years.1-6
Since 1999 we have been working on a percutaneous
bioprosthetic bicuspid venous valve (BVV) consisting of
small intestinal submucosa (Cook Biotech) attached to a
stainless steel square stent (Cook Inc). We studied BVV
remodeling and endothelization with a long-term study in
the sheep jugular vein, and found it promising. These
studies demonstrated that small intestinal submucosa valve
is not thrombogenic because of early endothelization of
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doi:10.1016/j.jvs.2004.08.027both surfaces of the valve leaflets.5,7-9 Good function was
found in 88% of BVVs at up to 6 months of follow-up; only
12% exhibited decreased function due to valve tilting.5 To
eliminate occasional valve tilting a second-generation BVV
was developed and tested in sheep jugular vein for deploy-
ment, stability, and short-term function.
METHODS
The study involved 24 adult female sheep weighing
47.3 to 71.6 kg (mean, 60.3 kg), and altogether 48 BVVs
were implanted in jugular veins. The Institutional Animal
Care and Use Committee of the Oregon Health Sciences
University approved the study.
Devices. The second-generation BVV was similar to
the original bicuspid valve constructed of a small intestinal
submucosa membrane sutured to a square stent.5 The
square stent had a short barb at each bend to provide
anchors for the valve during placement. and the small
intestinal submucosa membrane was slit at the diagonal axis
of the stent to create the valve opening. To facilitate BVV
placement and to prevent tilting, an additional stent was
attached to the original valve. Two BVV designs made, one
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determine which design and metal should be used for the
future long-term study. Two BVV sizes were tested to fit
jugular vein diameters of 10 to 12 mm and 12 to 14 mm.
Z-stent BVV (ZS BVV). A modified 4-bend Z-stent
with barbs at the upper bends was attached to the apex of
the original valve (Fig 1, A). Altogether, 16 ZS BVVs were
tested, 8 made of stainless steel and 8 made of nitinol.
Double-stent BVV (DS BVV). In this BVV design a
second square stent without barbs was added to the mid-
point of the original valve (Fig 1, B ). Altogether, 32 DS
BVVs were tested, 4 made of stainless steel and 28 made of
nitinol. Only 4 hand-made stainless steel DS BVVs were
constructed because of inconsistent expansive forces of the
double-stent valve frame. We tested 16 more DS BVVs
than ZS BVVs because 2 overlapping square stents were
shorter than Z-stents, and were providing less extra points
where the device contacted the inner wall of the vessel.
Delivery system. The 110-cm long delivery system
consists of an introducer sheath with a marked tip and
Tuohy Borst adapter (Cook) and dilator with a cutout for
the BVV. Nitinol BVVs were deployed with a 10F sheath
and stainless steel BVVs with a 13F sheath. The lyophilized
BVVs were front-loaded in the sheath.
Valve implantation. The areas around the distal neck
and right groin were prepared. A 7F Teflon vascular sheath
(Cook Inc) was introduced percutaneously into each jugu-
lar vein and a right femoral vein, and heparin 100 IU/kg
was administered intravenously. Simultaneous bilateral jug-
ular venograms were then obtained in the right and left
oblique views, with the animal in the Trendelenburg posi-
tion (30-40 degrees), with anOEC/GE 9800. Jugular vein
Fig 1. Second-generation bioprosthetic venous valve. A
stent valve. Z-stent has barbs at its upper bends. B,Nonr
4 barbs for maximal vein diameter of 12 to 14 mm.diameter was measured in both views in the area of theintended vein implantation with an 0.035-inch graduate
measuring guide wire (Cook Inc) for calibration. A BVV
with approximately the same diameter as the jugular vein
was selected and rehydrated at least 10 minutes before
implantation with 10 mL of heparinized saline solution
injected through the side arm of the sheath. A 260-cm long
extra-stiff wire (Cook Inc) was then introduced via the
femoral sheath into the jugular vein wiht an H1 curved
catheter (Cook Inc). The 7F sheath was then exchanged for
either the 10F or 13F delivery sheath. BVVs were delivered
into both jugular veins across the natural valve and above
the jugular vein confluence with the subclavian vein
through a right femoral approach. During delivery the BVV
with barbs self-attached to the vein wall. The dilator and
guide wire were then removed, and the sheath was left in
the superior vena cava for follow-up venograms with a 6F
side-hole catheter. BVVs were studied for function and
stability in the Trendelenburg position (30-40 degrees) by
injecting contrast medium, 20 mL/s, for 2 seconds below
and above the BVV. Grading of reflux was assessed as
reported by Kistner et al.10
Follow-up. Six weeks after BVV implantation the an-
imals were returned to the research laboratory to undergo
descending and ascending venography and then were eu-
thanized. Tilting of the valve was measured in the bicuspid
view as an off-center deviation of the valve frame from the
longitudinal vessel axis. Migration of the valve was mea-
sured in the bicuspid view as movement of the device from
post-placement location to another location inside the
vessel.
Gross examination and histologic study. Gross ex-
aminations focused on the jugular vein and surrounding
inless steel Z-stent is attached to apex of original square
ned nitinol double-stent bioprosthetic venous valve with, Sta
estraistructures. Jugular veins with BVVs were photographed
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formalin and embedded in methylmethacrylate for histo-
logic examinations. The other 44 veins were stored in saline
solution and sent to the manufacturer for in vitro testing.
Statistical analysis. Results are reported as mean 
STDEV, number, and percentage of competent valves at
6-week follow-up. We used analysis of variance with post
hoc testing (analysis of variance; SPSS software) to examine
angiographic competency differences between 4 groups of
BVVs at 6-week follow-up. P  .05 was considered
significant.
RESULTS
Venographic results of BVV placement are summarized
in the Table. Jugular vein diameter ranged from 9.8 to 14.4
mm (mean, 12.1  1.2 mm). BVVs sizes approximated
vein diameters. The 10-mm to 12-mm valve was deployed
in 27 jugular veins, and the 12-mm to 14-mm valve in 21
jugular veins. Placement of all 48 BVVs was successful, with
no tilting ormigration. All valves exhibited 100% patency at
implantation and on 6-week venograms. Good function
with no or minimal leak was seen in all valves on immediate
venograms, and in 44 of 48 (91.6 %) BVVs at 6 weeks (Fig
2). Angiographic competency for the nitinol ZS BVV
(100%; P 1.00), stainless steel ZS BVV (100%; P 1.00,
and nitinol DS BVV (92.3%; P .488) was not significantly
different between the 3 devices but was significantly better
than stainless steel DS BVV competency at 6 weeks (50%;
P  .03).
Four valves exhibited poor function, with significant
leak noted on follow-up venograms. These included 2
stainless steel DS BVVs that were placed in the same size
jugular vein and 2 12-mm to 14-mm nitinol DS BVVs
placed in 11-mm and 11.1-mm diameter jugular veins,
respectively.
Gross examination. Examinations of exposed veins
revealed all BVVs securely anchored against the jugular vein
wall. The veins at the point of attachment were distended
from pressure of the BVV frame wires. No reaction or
damage to the surrounding structures was present. There
were no signs of vein disruption. All specimens were throm-
bus free. The metal frames of the BVVs were completely or
partially incorporated into the vein wall by neointimal
tissue (Fig 3).
The 2 incompetent stainless steel DS BVVs had exces-
sive intimal hyperplasia at the cusp attachment to the vein
Results of second-generation BVV placement in jugular ve
Valve design
BVV placed
n No tilt Pate
Stainless steel ZS BVV 8 8
Nitinol ZS BVV 8 8
Stainless steel DS BVV 4 4
Nitinol DS BVV 28 28 2
BVV, Bioprosthetic venous valve; ZS, Z-stent; DS, double stent.wall. Intimal hyperplasia extended from the valve attach-ment point to both leaflets and the vein wall, preventing
complete closure of the valve. One of the leaflets of the
other 2 leaky valves, which were oversized, was completely
fused, and 1 was partially fused with the vein wall.
Histologic analysis. Our histologic findings are based
on 4 randomly selected nitinol DS BVVs only. Early re-
modeling of the small intestinal submucosa leaflets with
endothelial and host connective tissue cells was found in all
selected nitinol DS BVVs (Fig 3).
DISCUSSION
Biomaterials have potential advantages over synthetic
Fig 2. Function of double-stent bioprosthetic venous valve
placed in sheep jugular vein 11 mm in diameter at 6-week follow-
up. A, Jugular venogram with injection above valve demonstrates
valve patency. B, High-volume injection of contrast medium be-
low valve does not reveal any reflux, and demonstrates valve
closure.
24 sheep
ediate venogram 6-Week venogram
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8materials as coverings for percutaneous venous valve.3-8
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small intestinal submucosa permitted manufacture of a
BVV that was anatomically similar to native valve.3,5 Our
previous experimental work with BVVs demonstrated re-
modeling of small intestinal submucosa with host cells and
endothelization on both sides of valve leaflets.5,8 The new
valve is a sturdier, second-generation version of a device
invented several years ago.3,5 The addition of overlapping
square stent or attachment of the Z-stent to the original
valve provided extra points where the device contacted the
inner wall of the vessel.
The new BVVs self-centered in the veins, and no tilting
was seen in any of 48 jugular veins. Sheep jugular veins were
used because of their similar size to human femoral veins.
The expanded BVVs with their 2 pockets were anatomically
and functionally similar to natural valves. On venograms
obtained immediately after placement, all 48 valves were
competent except for minimal reflux around the valves
because the small intestinal submucosa membrane was not
Fig 3. Specimen and histologic analysis of 10-mm to 12
jugular vein 11 mm in diameter at 6-week follow-up. A,
wall. B, Longitudinally cut specimen shows smooth, alm
venous valve into vein wall. C, Longitudinal microscopic
tion 2). D, Magnified view of early remodeled small in
cells, as previously described5,8 (hematoxylin-eosin stainyet completely attached to the vein wall. Remodeling byhost cells from the venous wall and circulating cells fused
the small intestinal submucosa membrane to the wall and
prevented reflux in 44 valves (91.6%), as seen on venograms
at 6-week follow up. Incompetence in 2 of the 4 valves was
related to expansion by the added stainless steel square
stent, which caused significant intimal hyperplasia and valve
insufficiency. Oversized valves (12 mm–14 mm) placed
into 11.0-mm and 11.1-mm jugular veins resulted in in-
competence of the remaining 2 nitinol DS BVVs.
Exact sizing, matching valve size with vein diameter, is
essential for good valve function. The vein at the site of
intended valve placement should be measured in maximal
distention in 2 projections. We measured jugular veins in
sheep in the Trendelenburg position. In patients an upright
position for venography or duplex ultrasound scanning will
be necessary to measure maximal femoral vein diameter
when the vein is well distended and rounded. The natural
valve below the entrance of a venous tributary where the
vein is larger is the optimal site for BVV placement. Use of
double-stent bioprosthetic venous valve placed in sheep
view from above shows incorporation of valve into vein
mplete incorporation of the double-stent bioprosthetic
of small intestinal submucosa leaflet (original mgnifica-
al submucosa leaflet reveals endothelial and other host
inal magnification 200).-mm
Axial
ost co
view
testina 10% to 15% undersized valve enables the valve to stretch
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migration in most cases. Oversized valves of 15% to 20%
vein diameter may lead to valve insufficiency because the
valve leaflets remain close to the vein wall and could fuse to
the vein wall during small intestinal submucosa remodel-
ing.
The importance of exact valve sizing and proper site
selection was demonstrated in our first 3 patients with
advanced deep chronic venous insufficiency.7,9 The correct
size of the original BVV placed in the venous sinus of the
incompetent natural valve in 2 patients resulted in symp-
tomatic improvement in both patients. One patient’s active
ulcer healed in 1 month after valve placement, and both
patients were relieved of severe venous claudication. One-
year follow-up duplex ultrasound scans documented good
valve function with only minor reflux. In the third patient
the BVV failed to function properly because it was mis-
placed lower than intended and therefore became over-
sized. None of these 3 original BVVs resulted in venous
thrombosis after more than 1-year follow-up.7,9
The study involved 4 second-generation BVVs made by
attaching to a first-generationBVV a second square orZ-stent
made of either stainless steel or nitinol. Although the short-
term function of the stainless steel or nitinol ZS BVVs was
excellent, there were drawbacks to this and the stainless steel
DS BVV design. Stainless steel BVVs required large, 13F
introductory sheaths, and were labor-intensive to fabricate
because they had to be made by hand. The overlapping
stainless steel square stent with its significant expansible force
on the venous wall led to intimal hyperplasia. The additional
Z-stent increased the length and size of the valve. The ZS-
BVV may not guarantee adequate valve centering in some
locations, such as the proximal femoral vein, owing to the
deep femoral vein and larger common femoral vein diameters.
Drawbacks to BVVs made of stainless steel and those con-structedwith an additional Z-stent directed our further efforts
to concentrate on the nitinol DS-BVV.
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